Cyclodextrins are popular drug solubilizers, but the use of the natural cyclodextrins is hampered by their tendency to co-precipitate with the drug. To understand and overcome such problems, we have studied the solubility of dexamethasone in the presence of natural β-cyclodextrin and γcyclodextrin, individually and in various combinations. Equilibrium models of the phase-solubility diagrams with individual cyclodextrins revealed that dexamethasone was solubilized as 1:1 complexes, but formation of insoluble higher-order complexes set an upper limit to the concentration of solubilized dexamethasone. This limit could be raised from 8 mM to 17 mM by using combinations of the two cyclodextrins, as their solubilizing properties were additive in some regions of the phase-solubility diagram and synergistic in other regions. The additive effects arise from the additivity of solubilities -same phenomenon contributes to the good solubilizing properties of many modified cyclodextrins. The synergistic effects, however, could not be explained. The results open up for an increased use of the natural cyclodextrins as an improved alternative to modified cyclodextrins.
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Introduction
Cyclodextrins (CDs) are often used drug solubilizers due to their ability to form water-soluble inclusion complexes with a large variety of drug molecules. 1 The cyclic structure of CDs consists of typically 6, 7, or 8 linked glucose monomers, termed α, β, and γCD, respectively. Depending on the diameter, CDs may encapsulate drug moieties of various sizes. In addition to these so-called natural CDs, a large number of chemically modified CDs have been synthesized, the most common being hydroxypropylated, sulfobutylated, and methylated CDs. These modified CDs have a higher aqueous solubility and an often improved toxicological profile compared to their parent CDs. 2 In contrast to the natural CDs, they are highly heterogeneous samples, containing a variety of CDs differing in the degree and pattern of substitution.
The drug-solubilizing properties of a given CD is often studied by phase-solubility (PS) analysis in which the concentration of dissolved drug is plotted against the amount of added CD. 3, 4 There seems to be a general tendency for modified CDs to result in A-type PS profiles in which the concentration of dissolved drug increases monotonously with the amount of added CD. In contrast, the natural β and γCD often exhibit B-type profiles in which the formed complexes have a limited solubility and precipitate from the solution. 4 Such behavior is problematic and may limit the use of natural β and γCD. On the other hand, the natural CDs often have higher binding constants, meaning that less CD is required to solubilize a given amount of drug. This may be of importance in solid oral dosage forms where the bulk formulation preferably should be contained in a single tablet of limited size. 5 Further, the complex sample composition of the modified CDs may be a drawback in terms of sample characterization, batch-to-batch variations and related regulatory issues. In order to improve the use of the natural CDs, it is desirable to understand why they, in contrast to the modified CDs, have B-type profiles and to discover methods to overcome this problematic behavior.
It has previously been discovered that addition of small amounts of HPγCD to natural γCD significantly improves the complexation efficiency of the latter. 6 This synergistic effect was speculated to be related to the formation of aggregates of CDs and their complexes, 7 but this hypothesis is difficult to prove due to the presumably short-lived and complex nature of the aggregates. The present work aims to shed light on the causes for the reported synergistic effects and to understand why the solubilizing properties of natural and modified CDs are so different. To keep things simple, the complex mixtures of modified CDs were avoided, and the solubilizing properties of two pure CDs, βCD and γCD, were studied individually and in various mixing ratios. Dexamethasone (DX) was chosen as drug molecule as the reported synergistic effects were observed for this particular drug. Like most other steroids, DX is known to give BS-type PS profiles with natural β and γCD and AL-type profiles with modified CDs. [8] [9] [10] [11] [12] [13] Further, the molecular mechanisms behind the PS diagram of γCD with the structurally similar steroid hydrocortisone were recently described in detail. 14 It seems feasible to obtain a similar mechanistic understanding of the current system consisting of one drug and two CDs. Such understanding may be extended to complex mixtures of CDs, like the modified CDs, and may explain the reported synergistic effects.
Ultimately, we hope this study can contribute to overcoming the problems associated with the low solubility of many drug complexes with natural β and γCD.
Theoretical Background PS diagrams are constructed by measuring the total solubility of a fixed amount of solid substrate (S, in this work DX) in a medium containing increasing amounts of solubilizer or ligand (L, in this work CD). The theoretical framework for the various types of PS diagrams were laid out by Higuchi and Connors in 1965 3 and later developed for several special cases of BS -type PS diagrams. [14] [15] [16] The interested reader is referred to these references for details; the present text only highlights the main points.
BS-type PS profiles occur when one of the formed complexes has a limited solubility and precipitates from the solution. In the present case, DX forms soluble 1:1 complexes and insoluble higher-order complexes with both CDs. As shown in Figure 2 , this gives rise to three regions in the PS diagram. In region I, the DX concentration in the liquid phase increases linearly with increasing amounts of CD. In region II, all concentrations are constant as the precipitate consists of two solid phases of respectively precipitated higher-order complex and solid DX. This maintains constant concentrations of all dissolved species. Region III occurs when enough CD has been added such that all solid DX is solubilized or has precipitated as higher-order complexes. The absence of solid DX permits the concentration of free DX to go below its intrinsic solubility, S0, and continued addition of CD will gradually deplete DX from the solution and precipitate it as higher-order complex.
The mathematical modelling rests on a set of equations based on mass conservation and chemical equilibria. The relevant mass conservations relates to the total concentrations of DX (Seq) and CD (Leq) in solution:
and to the distribution of molecules between solution and precipitate:
St and Lt are the total amounts of DX and CD added to the vial, and LxSy prec is the amount of higherorder complexes in the precipitate.
The concentration of 1:1 complexes, [LS] , is governed by the binding constant: ) and the precipitation of higher-order complexes is determined by the solubility product:
Solving this system of equations with the region-specific constraints yields the concentrations of the dissolved species, as shown in the Supporting Information. It is important to note that the model assumes that no higher-order complexes (x > 1 and/or y > 1) are present in the liquid phase. Such complexes may only be present in the solid phase. For this reason, no concentrations of higherorder complexes appear in the equations and no equilibrium constant for the formation of higherorder complexes in the liquid phase is defined. These are omitted from the model as the presently studied systems turned out to behave similarly to a previous study of hydrocortisone and γCD in which no higher-order complexes were present in solution. 14 
Experimental Section
Chemicals β-cyclodextrin (purity ≥ 97%) and γ-cyclodextrin (purity ≥ 98%) were purchased form Sigma-Aldrich. The water content of the cyclodextrins (11.26 ± 0.08wt% for βCD, 9.07 ± 0.05wt% for γCD) was determined from the mass loss upon drying. Dexamethasone (96% purity) was from Acros Organics. Milli-Q water was used for all solutions.
Isothermal titration calorimetry
To determine the binding constants of DX to each the two CDs calorimetric titrations were made on 
Dexamethasone solubilized by γ-cyclodextrin
The PS diagram for DX solubilized by γCD was generated by adding a constant amount of solid DX, corresponding to 32.3 mM, to each vial and measuring the equilibrium concentration of DX in the aqueous phase. In the absence of γCD, the intrinsic solubility of DX was determined to 0.164 mM ± 0.005 mM (±SD, n = 3). As the concentration of γCD in the added aqueous solvent increased, the amount of solubilized DX first increased linearly, then reached a plateau, followed by a sharp decrease. The resulting BS-type PS diagram is shown in Figure 2 . From the length of region II the precipitation stoichiometry was determined to 1.48, 3 thus indicating that γCD and DX precipitated in a ratio of three γCDs to two DX molecules. It therefore seems appropriate to model the experimental data using a 3:2 model in which x and y in eq. 7 are 3 and 2, respectively. The black line in Figure 2 shows the prediction of the 3:2 model. Out of the three parameters that determines the shape of the model prediction, two of the parameters, K and S0, had already been determined by ITC and solubility measurements, respectively. The third parameter 32 was determined from the height of the plateau in region II (6.95 ± 0.09 mM) using eq. 8 (derived as eq. S5 in the Supporting Information):
where is the height of the plateau. This yields 32 = 0.78 mM 5 . Dexamethasone solubilized by β-cyclodextrin
As for γCD, the solubilization of DX by βCD also resulted in a BS-type PS diagram (Figure 3 ) but with a second plateau which will be termed region IIA. In region II, the precipitate consists of two solid phases: pure DX and precipitated higher-order complex. In region IIA, the solubility of βCD was reached, and the precipitate consisted of a solid phase of pure βCD and another solid phase of precipitated higher-order complex. The length of the region II plateau indicated that βCD and DX precipitated in a ratio of 2:1 (CD to DX), and therefore the data were modeled by a 2:1 model in which DX is solubilized as 1:1 CD complexes and precipitated as 2:1 complexes. In addition to the 1:1 binding constant and the intrinsic solubility of DX, which were determined by ITC and solubility measurements, the model employs the 2:1 CD:DX solubility product, 21 . Further, to describe region IIA, the intrinsic solubility of βCD, L0, was set to the previously reported value of 16.3 mM at 25°C. 21 The value of 21 can be determined from the height of the region II plateau, as was done for γCD, but due to the more precise determination of the plateau in region IIA (4.42 ± 0.06 mM), this value was used to determine 21 according to eq. 8 (derived as eq. S10 in the SI) where L0 is the intrinsic solubility of βCD: As seen on Figure 4A the concentration of DX increases linearly up to a total CD concentration of around 35 mM. At this point, the DX concentration reaches 18 mM which is more than twice as high as in the experiments with the individual CDs. There is some scatter on the plot which is expected as the DX solubility is not unequivocally given by the total CD concentration but depends on the relative amounts of βCD or γCD. Since γCD is a more efficient solubilizer than βCD, samples with a higher ratio of γCD to βCD can solubilize more DX, even if the total CD concentration is the same.
If the presence of two different kinds of CDs does not result in any new species, such as new types
of complexes or aggregates, the total concentration of solubilized DX should be equal to the sum of free DX and DX complexed with βCD and γCD:
This can be expressed as:
where Kβ and Kγ are the 1:1 binding constants, and βCDt and γCDt are the amounts of added CDs, expressed as concentrations. There was a small difference between the binding constants determined by ITC and those determined from region I of the individual PS diagrams. Insertion of the latter into eq. 11 yields an excellent agreement between the observed and predicted concentrations, as shown in Figure 4B 
Strong synergistic effect in region IIA
The modelling in Figure 5 shows that two samples are inside region IIA. This region is characterized by the presence of pure solid βCD, the presence of which was confirmed by a small endothermic peak at 220-225°C in the DSC curves. 22 Solid βCD was also identified in the sample right before region IIA (at 70 mM added βCD) but not in any other samples. The attribution of this peak to solid βCD is supported by its presence in all of the region IIA samples of the PS diagram with βCD where the peak area was roughly proportional to the amount of solid βCD. The additive model predicts a DX concentration of 8.9 mM but the measured concentrations were around 15 mM, clearly showing a strong synergistic effect.
Discussion
The PS diagrams of DX with the individual CDs were well described by equilibrium models in which DX forms water-soluble 1:1 complexes with CD and precipitates as higher-order complexes.
Precipitation takes place when the product of the concentrations exceeds the solubility product of the precipitate. For βCD, precipitation occurs when the total concentration of βCD exceeds 17 mM.
At this point, the concentration of DX is 7.9 mM, and this is the maximum amount of DX that can be solubilized by βCD. γCD can solubilize up to 7 mM DX, which requires addition of 10 mM γCD. When both CDs are present, the solubilizing effects are additive, and the apparent solubility of DX can reach 17 mM. This is because the linearly increasing part of the PS diagram is extended, and precipitation does not occur until a total of more than 30 mM CD has been added. Most modified CDs, such as partially methylated, sulfobutylated and hydroxypropylated CDs, are complex mixtures containing hundreds of CD isomers and homologues. Each of these isomers may in principle precipitate with a drug, but as the concentration of each isomer is very low precipitation will not occur. This is probably the reason why modified CDs give A-type PS diagrams. Same phenomenon contributes to the increased solubility of modified CDs for which the solubility is the sum of the independent solubilities of its components. 23 The present work shows that this "multiple component effect" can be exploited to improve the solubilizing properties of the natural CDs, thereby expanding their usage.
Precipitation of complexes is not a problem that is limited to the natural CDs. All pure CDs may suffer from this limitation. For example, two promising neutral βCD thioethers with a strong affinity for steroids turned out to be poor solubilizers due to precipitation of complexes. 24 Mixtures of high-affinity CDs may to some extent alleviate such problems and form a strong-binding alternative to the conventional modified CDs.
The additive model assumes that the apparent solubility of DX is given as the sum of [DX],
[βCD:DX] and [γCD:DX] (eq. 10), and that these concentrations in turn are given by the complexation constants for the 1:1 complexes and the solubility products of the precipitated entities (eq. 6 and 7). In other words, the equilibria that describes the PS diagrams with the individual CDs are assumed to describe the solubility of DX when both CDs are present. In region I, when no CDs had precipitated, the combined effect of β and γCD was well described by the additive model. In contrast, synergistic effects were observed in region II and region IIA of the PS diagram with the CD mixtures. This indicates that other equilibria than those described by equations 6 and 7 become relevant. We speculate that additional soluble species may form, for instance a 1: The phase-solubility diagram of DX with mixtures of βCD or γCD reveals not only additive but also significant synergistic effects in some regions of the phase solubility diagram. This suggests the presence of additional species in solution, but this explanation is so far purely speculative.
